Health ❯ Healthcare ❯ Clinical Trials ❯ Phase III Trials

POTOMAC Trial

FDA Approves Durvalumab Plus BCG for High‑Risk Non‑Muscle Invasive Bladder Cancer

Phase 3 data showing lower recurrence alongside longer disease‑free survival support a new adjuvant immunotherapy option for patients who have not had BCG.